The news that PercuSurge, the leader in emboli collection/protection devices, had been purchased by Medtronic caused some medical device executives to shake their heads in disbelief. Many had viewed a much-anticipated PercuSurge IPO as one of the most promising in the device industry in years, and they were confident that the device itself has the potential to be a blockbuster. That blockbuster potential, combined with the $225 million price tag, made it seem, frankly, as if PercuSurge had given up too early and too easily. But executives close to PercuSurge defended the company's move while affirming the long-term potential of the device.
The news, announced the first day of this year's TCT
(Transcatheter Cardiovascular Therapeutics) conference in
Washington, that PercuSurge Inc. , the
leader in emboli collection/protection devices, had been purchased
by Medtronic Inc. caused some medical
device executives to shake their heads in disbelief [See Deal].
Many had viewed a much-anticipated PercuSurge IPO as one of the
most promising in the device industry in years, and they were
confident that the device itself has the potential to be a
blockbuster.
That blockbuster potential, combined with the $225 million price tag, made it seem, frankly, as if PercuSurge had given up...
